MX2009004007A - Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Info

Publication number
MX2009004007A
MX2009004007A MX2009004007A MX2009004007A MX2009004007A MX 2009004007 A MX2009004007 A MX 2009004007A MX 2009004007 A MX2009004007 A MX 2009004007A MX 2009004007 A MX2009004007 A MX 2009004007A MX 2009004007 A MX2009004007 A MX 2009004007A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
indole derivatives
novel indole
Prior art date
Application number
MX2009004007A
Other languages
English (en)
Inventor
Daniel-Henri Caignard
Philippe Delagrange
Valerie Audinot
Pascal Marchand
Sylvie Piessard
Muriel Duflos
Jean Albert Boutin
Vincet Babonneau
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2009004007A publication Critical patent/MX2009004007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Los compuestos de la fórmula (I), en la cual: R1 es un grupo alquilo, cicloalquilo o cicloalquilalquilo; R2 es un grupo alquilo (C1-C6), lineal o ramificado; y n es 1 a 6; medicamentos.
MX2009004007A 2006-10-18 2007-10-17 Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen. MX2009004007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609114A FR2907452B1 (fr) 2006-10-18 2006-10-18 "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2007/001707 WO2008049996A2 (fr) 2006-10-18 2007-10-17 Nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
MX2009004007A true MX2009004007A (es) 2009-04-27

Family

ID=37944765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004007A MX2009004007A (es) 2006-10-18 2007-10-17 Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Country Status (17)

Country Link
US (1) US8003682B2 (es)
EP (1) EP2086933A2 (es)
JP (1) JP2010506889A (es)
KR (1) KR20090089323A (es)
CN (1) CN101522617A (es)
AU (1) AU2007310769B2 (es)
BR (1) BRPI0717453A2 (es)
CA (1) CA2666497A1 (es)
EA (1) EA200900480A1 (es)
FR (1) FR2907452B1 (es)
GE (1) GEP20115192B (es)
MA (1) MA30795B1 (es)
MX (1) MX2009004007A (es)
NO (1) NO20091794L (es)
UA (1) UA91646C2 (es)
WO (1) WO2008049996A2 (es)
ZA (1) ZA200902413B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000272667A1 (en) 2000-09-13 2002-04-29 Jiangsu Kanion Pharmaceutical Co. Pharmaceutical composition treating gynecological blood stasis diseases, cardio and cerebral vascular diseases, respiratory diseases and the like
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
KR102467709B1 (ko) 2015-03-27 2022-11-15 가부시키가이샤 코세 리포솜 조성물

Also Published As

Publication number Publication date
GEP20115192B (en) 2011-03-25
CA2666497A1 (fr) 2008-05-02
WO2008049996A3 (fr) 2008-06-19
NO20091794L (no) 2009-05-06
UA91646C2 (ru) 2010-08-10
WO2008049996A2 (fr) 2008-05-02
CN101522617A (zh) 2009-09-02
BRPI0717453A2 (pt) 2013-12-24
EA200900480A1 (ru) 2009-10-30
FR2907452A1 (fr) 2008-04-25
MA30795B1 (fr) 2009-10-01
AU2007310769A1 (en) 2008-05-02
US20100063128A1 (en) 2010-03-11
JP2010506889A (ja) 2010-03-04
AU2007310769B2 (en) 2011-08-11
FR2907452B1 (fr) 2008-12-12
KR20090089323A (ko) 2009-08-21
US8003682B2 (en) 2011-08-23
EP2086933A2 (fr) 2009-08-12
ZA200902413B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
TW200833326A (en) Chemical compounds 572
TW200716511A (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
NO20091560L (no) Biaryleterureaforbindelser
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
WO2009110985A3 (en) Amide compounds, compositions and uses thereof
NO20084005L (no) Aminderivater
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
MX2009005507A (es) Derivados de espiro-piperidina.
CY1111429T1 (el) 1,3-διυποκατεστημενα αμιδια 4-μεθυλο-1η-πυρρολο-2-καρβονικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
GEP20115240B (en) Indole derivatives, process for their preparation and pharmaceutical compositions containing them
MX2009004007A (es) Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
MY144746A (en) Process for the preparation of agomelatine
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
RS20090211A (en) Pyrazole analogs
GEP20125563B (en) 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same
MX2011005971A (es) Nuevas formas polimorficas de un derivado de azabiciclo-trifluorom etil benzamida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal